

RESEARCH ETHICS BOARD (REB) INTERNAL SERIOUS ADVERSE EVENT (SAE) REPORTING FORM

NYGH NYGH Principal REB #: Investigator (PI) Name:							Person Con Name: Role:							
PROTOCOL TITLE:					Drug/Device/Intervention:		vention:	Sponsor:			Does study have a DSMB: ☐ Yes ☐ No			
								Response to		Relationship to Study Intervention				
Date first member of steam awar the SAE (dd-mm-yy	study e of Code	Onset Date & Resolution Date of SAE	Туре	Type Name or I Term of S		1 = Dea 2 = Hos 3 = Me 4 = Rea	tient Outcome ath spitalization dical Interventi covered ner (specify)	1 = None 2 = Dose	Unexpected event	Related/ Probably Related	Possibly Related	Unlikely Related	Unrelate	
		Date:	☐ Initial ☐ F/Up ☐ Final						☐ Yes ☐ No					
Study action Yes	recommended No	(if Yes go to * below	w)					es this SAE meet the				e REB Guide	lines for	
* PI/Co-I rec	ommends chan	ges to:						Yes (The PI/Co-I atte	ests that the SAE ha	as been/will be su	ıbmitted to Hea	Ith Canada as	required.)	
Protocol Yes No	Consent ☐ Yes ☐ No	Consent IB ☐ Yes ☐ Yes		her changes Yes - Speci No	у:			□ No (The PI/Co-I attests that the SAE does not require submission to Health Canada.)						
	Summary of	Serious Adver	se Event:				·							
		pelow attests that I dy intervention and					igator (Co-I) l	nave reviewed the	SAE and its safe	ety implications,	assessed the	relationship	of the	
	Printed name of PI/Co-I				Signature of PI/Co-I			Date (dd/mmm/yyyy)						
	 Versi	on Date:00	ctober	2017										